Trials / Completed
CompletedNCT04985916
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 280 (actual)
- Sponsor
- Eirion Therapeutics Inc. · Industry
- Sex
- All
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Detailed description
This product is being tested for its ability to reduce lateral canthal lines (LCL), also known as Crow's Feet.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Vehicle | topical liniment without investigational product |
| BIOLOGICAL | botulinum toxin, Type A | ET-01 topical liniment |
Timeline
- Start date
- 2021-07-19
- Primary completion
- 2024-02-08
- Completion
- 2024-02-08
- First posted
- 2021-08-02
- Last updated
- 2024-12-09
Locations
19 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04985916. Inclusion in this directory is not an endorsement.